Johnson & Johnson’s Spravato, a nasal spray derived from ketamine, has reached blockbuster status with annual sales exceeding $1 billion. Approved in 2019 for treatment-resistant depression, the drug’s commercial success marks a significant shift in mainstream psychiatry toward psychedelic-inspired treatments. Unlike traditional antidepressants, Spravato requires clinical supervision during administration due to its potency. This growth is encouraging pharmaceutical companies and investors to further explore other psychedelic substances, such as psilocybin and MDMA, potentially transforming the landscape of mental health care and validating the medical utility of once-stigmatized substances.
- Spravato is a derivative of ketamine specifically approved for patients who have not responded to traditional antidepressants.
- The drug has generated approximately $1.7 billion in sales, establishing it as a major financial success for Johnson & Johnson.
- Patients must receive the treatment in a certified medical facility and remain under professional observation for two hours after administration.
- The commercial viability of Spravato is stimulating clinical research into other psychedelic compounds, including psilocybin for depression and MDMA for PTSD.
- This trend reflects an increasing acceptance of psychedelic-based medicine within the established global pharmaceutical industry.
Bloomberg is a privately held financial, software, data, and media company headquartered in New York City.
Official website: https://www.bloomberg.com/
Original video here.
This summary has been generated by AI.
The $1.7 Billion Trip: https://www.bloomberg.com/features/2026-jjs-spravato-psychedelic-blockbuster-drug/
How J&J leveraged insurance to turn Spravato into a blockbuster depression drug.
If disease don't get you , big pharma surely will 😐
Safe as the Covid Vaccine
Mark my words, companies will be caught pumping this shit through the HVAC, side effects be damned, and with no personal legal consequences- because Amerika.